CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.
CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.
复制标题
DOI:
10.1371/journal.pone.0066772
复制
发表时间:
2013
期刊:
影响因子:
3.7
通讯作者:
Karandikar NJ
中科院分区:
文献类型:
--
作者:
Tyler AF;Mendoza JP;Firan M;Karandikar NJ
The exact mechanism of glatiramer acetate (GA, Copaxone®), an FDA-approved immunomodulatory therapy for multiple sclerosis (MS), remains unclear after decades of research. Previously, we have shown that GA therapy of MS induces CD8+ T cell responses that can potentially suppress pathogenic CD4+ T cell responses. Using a murine model of MS, experimental autoimmune encephalomyelitis (EAE), we now demonstrate that CD8+ T cells are necessary in mediating the therapeutic effects of GA. Further, adoptive transfer of GA-induced CD8+ T cells resulted in amelioration of EAE, establishing a role as a viable immunotherapy in demyelinating disease. Generation of these cells required indoleamine-2,3-dioxygenase (IDO), while suppressive function depended on non-classical MHC class I, IFN-γ, and perforin expression. GA-induced regulatory myeloid cells, previously shown to activate CD4+ regulatory T cells in an antigen-independent manner, required CD8+ T cells for disease suppression in vivo. These studies demonstrate an essential role for CD8+ T cells in GA therapy and identify their potential as an adoptive immunotherapeutic agent.
登录
查看更多内容
影响因子:
3.3
作者:
Beeston, Tara;Smith, Trevor R. F.;Maricic, Igor;Tang, Xiaolei;Kumar, Vipin
通讯作者:
Kumar, Vipin
影响因子:
4.4
作者:
Jee, Y;Liu, RL;Vollmer, TL
通讯作者:
Vollmer, TL
影响因子:
4.4
作者:
Li, JF;Goldstein, I;Chess, L
通讯作者:
Chess, L
DOI:
10.1073/pnas.0810383105
发表时间:
2008-12-09
影响因子:
11.1
作者:
Lu, Linrong;Kim, Hye-Jung;Cantor, Harvey
通讯作者:
Cantor, Harvey
影响因子:
4.4
作者:
Hwu, P;Du, MX;Young, HA
通讯作者:
Young, HA